^
Association details:
| Biomarker: | MET exon 14 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | babamekip (ABN401) (c-MET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation
Excerpt:
......
Trial ID:
Source:
Title:
To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of ABN401 in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer Harboring c-MET Dysregulation
Excerpt:
...For the Phase 1 extension (pilot expansion), patients must have NSCLC with c-MET overexpression, MET amplification, or MET exon 14 skipping by local biomarker assessment as defined in study protocol....
Trial ID:
More C2 evidence
Source:
Title:
A Phase II Study of ABN401 in Advanced Solid Tumors With c-MET Gene Aberration
Excerpt:
...Histologically confirmed advanced solid cancers who harboring c-MET alterations (patients who performed NGS tests and c-MET alterations confirmed in molecular tumor board [MTB])...
Trial ID:
Less C2 evidence
Source:
Title:
ABN401 in patients with NSCLC with MET exon 14 (METex14) skipping: Result from the pilot expansion study.
Published date:
05/25/2023
Excerpt:
c-MET dysregulated (overexpression, amplification, and METex14 skipping) NSCLC pts were enrolled and received a daily dose of 800 mg ABN401 without experiencing any dose-limiting toxicities (DLTs)....Among all, 4 pts had METex14 skipping mutations, out of which 2 pts demonstrated partial responses to the therapy, and one patient had SD. One patient with MET amplification is now in SD and has been receiving treatment for approximately 16 months.
DOI:
10.1200/JCO.2023.41.16_suppl.e21148
Trial ID:
